Stem Cell TV | Video / Media News

Page 407«..10 20..406407408 409..420 430..»

First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics – Tech Times

Posted: June 4, 2022 at 2:33 am

Leading experts among 3D printing manufacturers and regenerative medicine company 3DBio Therapeutics have successfully performed a clinical trial of transplanting a 20-year-old female's ear utilizing a 3D-printed iteration made from the same female's cells.

The doctors involved relayed key details surrounding the trial amid a press release, yet had to refrain from fully unearthing all of the secrets behind their efforts with the so-called AuriNovo ear due to proprietary concerns.

The woman treated with the 3D-printed ear implant suffered from a rare genetic birth deformity, called microtia, which either causes one or both ears to not grow at all or grow in an underdeveloped manner.

Nearly 1,500 US children are born with the condition, thus spurring 3DBio Therapeutics to enact a clinical trial involving so far a total of 11 participants with their AuriNovo ear implant.

The 3D printed ear implant relies on the client's own tissue to replace their deformed or missing ear. Usually, such patients suffering from microtia accept grafts taken from their ribs or alternative synthetic materials, but 3DBio Therapeutics does it vastly differently, as the tissue engineering and regenerative medicine company instead opts to leverage the patient's cartilage cells from the existing ear following a biopsy.

Related Article:Pig Heart Transplant Patient Dies, Cause of Death Unknown-Xenotransplantation Not Yet Effective?

From there, the team takes the cells and grows them via 3D printing technology, shaping the newly-formed product into the patient's ear.

Utilizing the patient's own cells ensures that the AuriNovo ear will be less likely to be rejected from the client. Plus, over time, the new appendage will continue regenerating throughout that particular patient's life.

"This is truly a historic moment for patients with microtia, and more broadly, for the regenerative medicine field as we are beginning to demonstrate the real-world application of next-generation tissue engineering technology," says Chief Executive Officer and co-founder of 3DBio Therapeutics, Daniel Cohen, within the press release. "It is the culmination of more than seven years of our company's focused efforts to develop a uniquely differentiated technology platform meeting the FDA's requirements for therapeutic manufacturing of reconstructive implants."

Similar advancements in the fields of tissue engineering and regenerative medicine have proven to witness astounding growth, evidenced best via a heart transplant initiated in early January of this year, wherein the patient was given a pig heart as substitute for their muscular organ.

Unfortunately, the patient would later die due to a viral pig infection, but does lend credence to the potential of 3D printed heart transplants, and continued tissue engineering efforts in line with stem cell research.

The groundbreaking achievement provided via 3DBio Therapeutics was documented in a New York Times feature, wherein both doctors voiced even more information surrounding their 3D printed ear transplant.

Of those involved in the procedure, San Antonia's pediatric ear reconstructive surgeon Dr. Arturo Bonilla offered the most heartwarming of all considerations on the future of the AuriNovo project:

"This is so exciting, sometimes I have to temper myself a little bit. If everything goes as planned, this will revolutionize the way this is done."

Read Also:Scientists Successfully 3D Print Human Corneas; This Breakthrough Can Be the Solution for Transplant Shortage

This article is owned by Tech Times

Written by Ryan Epps

Posted in Stem Cell Research | Comments Off

How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into ‘Safer’ Covid-19 Vaccines: Study – ABP Live

Posted: June 4, 2022 at 2:30 am

New Delhi: A nanoparticle vaccine which combines two proteins that induce immune responses against SARS-CoV-2 has the potential to be developed into 'broader' and 'safe' Covid-19 vaccines, according to a new study.

The Covid-19 pandemic, or the SARS-CoV-2 pandemic, has claimed more than six million deaths since 2019, and is a public health burden worldwide. The rapid evolution of SARS-CoV-2 is characterised by the emergence of several significant variants, including Delta and Omicron.

The study, led by researchers in the Institute for Biomedical Sciences at Georgia State University, was recently published in the journal Small.

A nanoparticle-based vaccine is one in which the receptor-binding domain (RBD), which is a part of the spike protein of SARS-CoV-2, is attached to a protein designed to form nanometre-sized protein particles, or nanoparticles, according to a study by the US National Institutes of Health (NIH), which was published in the journal, Nature. SARS-CoV-2 attaches itself to cells using the spike protein.

These nanoparticles could be composed of lipids, metal and non-metal inorganics, several polymers, and virus-like particles which have been tested for research, according to a study published by the National Center for Biotechnology Information (NCBI), NIH. Virus-like-particles (VLP) are self-assembling nanoparticles lacking infectious nucleic acid.

Hyderabad-based Serum Institute of India's Covovax is a nanoparticle-based vaccine, manufactured by technology transfer from Novavax.

The spike protein (S) on SARS-CoV-2 is the preferred target antigen for vaccine development, based on its essential function and neutralising epitopes to combat the virus. An epitope is the part of an antigen molecule to which an antibody attaches itself.

The new study was conducted in mice, with the researchers investigating the immune response induced by two proteins, the spike protein and the relatively conserved stem subunit (S2) of the spike protein. The researchers found that the assembly of the two proteins into double-layered protein nanoparticles improves the immunogenicity of the proteins. Immunogenicity is defined as the ability of a molecule or substance to provoke an immune response.

In a statement released by Georgia State University, Dr Baozhong Wang, senior author of the study, said the entire S protein has been used as the major antigen in vaccines against the ongoing pandemic, adding that as the number of infections continues to rise, more and more variants have appeared and supplanted the ancestral virus.

Since the variants have superseded and replaced the ancestral virus, the efficacy and protection of current vaccines are under constant threat and need continuous improvement, Wang explained.

He further said that in contrast, the stem subunit of the spike protein is more conserved and has fewer mutations across lineages. He added that the stem could induce effective antibody neutralisation and vigorous antibody-dependent cellular cytotoxicity (ADCC) activity against multiple variants of S protein. ADCC, also known as antibody-dependent cell-mediated cytotoxicity, is a type of immune reaction in which a target cell or microbe is coated with antibodies and killed by certain types of white blood cells.

Wang explained that the work shows that the stabilised stem subunit could be a potential antigen for a SARS-CoV-2 universal vaccine against unpredictable variants.

According to the study, immunisation with the stem-induced balanced Immunoglobulin G (IgG) antibodies occurred through potent and broad ADCC activity, which is a type of immune reaction on which infected cells are coated with antibodies that recruit certain types of white blood cells to kill the infected cells. The study also found that the double-layered protein nanoparticles constructed from the stem and the full-length spike protein induced more robust ADCC and neutralising antibodies than the stem and spike protein, respectively.

The nanoparticles were observed to produce more potent and balanced serum IgG antibodies than the corresponding soluble protein mixture. The researchers also found that the immune responses are sustained for at least four months after the immunisation.

The stem induces a more balanced IgG isotype antibody. In immunology, antibodies or immunoglobulins are classified into several types called isotopes or classes. The double-layered nanoparticles not only have a more balanced IgG isotype antibody induced by the stem, but also long-lasting immune responses, and excellent safety profiles. As a result, the nanoparticles have the potential to be developed into broader SARS-CoV-2 vaccines, the authors noted in the study.

Dr Yao Ma, the first author of the study, said the stabilised, conserved S2 stem subunit demonstrated its potential as a universal SARS-CoV-2 vaccine candidate against unpredictable variants. The double-layered protein nanoparticles incorporating the full-length spike protein and the S2 stem induced robust and long-term immune responses, and exhibited a safety profile in the primary studies, Ma added. This provides an option for current SARS-CoV-2 vaccine development.

Ma further said that the pandemic is far from over, and new variants continue to emerge and pose a massive threat to human health. In order to avoid another pandemic with an unpredictable new variant, the updating of vaccines needs to keep pace with the times.

Nanoparticles help improve vaccine efficacy, by targeting desired antigen-presenting cells to improve immunisation strategies. They protect the antigen (foreign particle) from early proteolytic degradation (degradation of protein by hydrolytic enzymes), control antigen release, and facilitate antigen uptake.

Current vaccines cause cells in the body to make a version of the spike protein to elicit an immune response. Putting multiple copies of the RBD on nanoparticles enhances immune response, recent studies have found. The NIH researchers tested nanoparticle-based vaccines in monkeys and found that most of the monkeys had no virus in their lower respiratory tracts two days after exposure.

Nanoparticle-based vaccines contain a strand of genetic code that provides instructions for building a version of the spike protein, according to an article by the University of Pittsburgh Medical Center, US. Host cells build the protein when they see the genetic code.

The immune system begins building antibodies against the protein, which help the immune system fight the coronavirus. The body builds up an army of antibodies, which can fight off a Covid-19 infection before it causes disease.

Since mRNA is very fragile on its own, it would degrade in the body if it is injected simply as a strand. Hence, the genetic material is protected with a nanoparticle, which preserves the mRNA long enough to carry it into the bodys cells so that they can begin making the proteins.

The use of nanoparticles in vaccine formulations allows not only improved antigen stability and immunogenicity, but also targeted delivery and slow release, according to a article published in the journal, Elsevier.

Check out below Health Tools-Calculate Your Body Mass Index ( BMI )

Calculate The Age Through Age Calculator

See the original post:
How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into 'Safer' Covid-19 Vaccines: Study - ABP Live

Posted in Georgia Stem Cells | Comments Off

Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? – Kaiser Health News

Posted: June 4, 2022 at 2:28 am

Researchers point out that another pancreatic cancer patient who received the same therapy did not respond to the treatment and died. But the highly personalized immunotherapy is being called "an important step along the way to devising treatments that might help lung, colon, and other cancers.

The New York Times:Reprogrammed Cells Attack And Tame Pancreatic Cancer In One WomanResearchers have managed to tame pancreatic cancer in a woman whose cancer was far advanced and after other forms of treatment had failed. The experiment that helped her is complex and highly personalized and is not immediately applicable to most cancer patients. Another pancreatic cancer patient, who received the same treatment, did not respond and died of her disease. Nonetheless, a leading journal The New England Journal of Medicine published a report of the study on Wednesday. (Kolata, 6/1)

AP:Novel Genetic Experiment Shrinks Tough-To-Treat CancerIn a novel experiment, a woman with advanced pancreatic cancer saw her tumors dramatically shrink after researchers in Oregon turbocharged her own immune cells, highlighting a possible new way to someday treat a variety of cancers. Kathy Wilkes isnt cured but said whats left of her cancer has shown no sign of growth since the one-time treatment last June. I knew that regular chemotherapy would not save my life and I was going for the save, said Wilkes, of Ormond Beach, Florida, who tracked down a scientist thousands of miles away and asked that he attempt the experiment. (Neergaard, 6/1)

KGW8:Portland Doctors 'First In World' To Apply New Cancer TherapyDoctors at the Providence Cancer Institute (PCI) in Portland are celebrating the successful application of a new immunotherapy to drastically reduce a patient's tumor size. ... With this single-patient success story, Dr. Eric Tran, with Earle A. Chiles Research Institute, and Providence oncologist Dr. Rom Leidner plan to expand trials to treat 24 more patients over the next two to three years. They noted similar efforts have not always been successful. (Ettlin, 6/1)

Also

Stat:How Companies Are Responding To Cancer Immunotherapy ShortageThe shortage of manufacturing slots for CAR-T cells, which has left myeloma patients dying on a wait list, came as a surprise to drugmakers and clinicians alike. When the Food and Drug Administration approved the first myeloma CAR-T product from Bristol Myers Squibb in spring of 2021, there were already four other lymphoma and leukemia CAR-T therapies on the market. Those werent facing severe supply constraints so people hadnt expected there to be issues supplying ide-cel, Bristols myeloma CAR-T, said Yi Lin, the director of the cell therapy program at the Mayo Clinic. But after the approval, the demand quickly overwhelmed Bristols ability to create CAR-T for myeloma and supply chain issues during the pandemic made it more difficult to ramp up production. (Chen, 6/2)

Stat:'How Do You Decide?' Cancer Patients Die Waiting For CAR-T TherapyWithin two years of being diagnosed with multiple myeloma, Shawn Goltzene had blasted through nearly all his options. An initial stem cell transplant couldnt hold off the cancer for more than half a year. With each new therapy his doctors tried, the cancer would surge out of remission within weeks striking the bones in his back and legs. We hit him with everything, the whole kitchen sink, said Krina Patel, the director of the myeloma cell therapy program at MD Anderson Cancer Center and Goltzenes clinician. She tried putting him on a clinical trial for an immunotherapy drug. It blew right through him. He quickly got to fourth-line therapy. (Chen, 6/2)

Austin American-Statesman:Dell Medical School Trying To End Desert In Austin Bladder Cancer CareDorothy De La Garza had frequent urinary tract infections. Then she was told she had "an overactive bladder." "Everyone assumes a woman is leaking because she's old," the 78-year-old from Austin said. After years of being on antibiotics on and off, and going to both a urologist and her primary care doctor for the same symptoms, De La Garza was diagnosed with bladder cancer in 2016."Bladder cancer is sneaky," she said.(Villalpando, 5/31)

See the original post here:
Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News

Posted in Stem Cell Therapy | Comments Off

Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater…

Posted: June 4, 2022 at 2:28 am

The new report by Expert Market Research titled, GlobalHuman Embryonic Stem Cell MarketReport and Forecast 2022-2027, gives an in-depth analysis of the global human embryonic stem cell market, assessing the market based on its segments like applications and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Get a Free Sample Report with Table of Contents: https://bit.ly/3M9nlum

The key highlights of the report include:

Market Overview (2017-2027)

Historical Market Size (2020): USD 0.7 billion Forecast CAGR (2022-2027): 10%

The human embryonic stem cell market is being driven by the thriving medical sector. The rising demand for embryonic stem cells can be attributed to the increasing prevalence of chronic diseases around the world owing to the rising adoption of unhealthy and sedentary lifestyle among the youth and middle-class population. The increased risk of premature death as a result of chronic diseases is a growing concern. Therefore, human embryonic stem cells are gaining popularity in the medical sector. Furthermore, the increase in research grants and private as well as public funding for the development of effective and safe stem cell therapy products is further aiding the market growth. The rising investments from key players towards enhancing human embryonic cell therapy is expected to aid the market growth in the forecast period. In post-COVID days, as the various sectors recover from the negative impacts of the pandemic, human embryonic stem cells are likely to witness a rise in demand.

Industry Definition and Major Segments

Human embryonic stem cells, also known as human embryonic stem cells are self-replicating cells derived from human fetal tissue or human embryos that develop into tissues and cells of 3 primary layers. Furthermore, human embryonic stem cells are pluripotent and are roughly 3-5 days old. It is highly versatile, as it may split into new stem cells and even transform into any type of cell in the human body, allowing it to regenerate or repair any diseased organ or tissue.

Read Full Report with Table of Contents: https://bit.ly/3x9uczx

The human embryonic stem cell market, on the basis of application, can be segmented into:

Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing

The regional markets for human embryonic stem cell include:

North America Europe Asia Pacific Latin America Middle East and Africa

Among these, North America represents a significant share of the human embryonic stem cell market.

Market Trends

The rising population along with the rapidly evolving medical infrastructure of emerging economies like India and China is expected to provide an impetus to the human embryonic stem cell market. Furthermore, technological advancements and increasing research and development investments and initiatives are expected to generate opportunities in the market. Researchers and scientists are increasingly leaning toward the transformation of human embryonic stem cells into a number of mature cell types that represent various tissues and organs in the body, as embryonic cells provide unequalled data relating to a variety of disorders. The increasing efforts by the governments of various nations towards enhancing human embryonic stem cell therapy is likely to be another key trend bolstering the market growth in the forecast period.

Key Market Players

The major players in the market Astellas Pharma Inc, Stemcell Technologies Inc., Biotime INC, Thermo Fisher Scientific, Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The companys expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1,000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Dedication, Achievement and Grace in Cancer Care – Curetoday.com

Posted: June 4, 2022 at 2:28 am

In a field populated by highly skilled and deeply compassionate nursing oncology professionals, Kathryn Buttner, B.S.N., RN, BMTCN, director of stem cell transplant and cellular therapy at the John Theurer Cancer Center, stands out by fulfilling her role with unique dedication, significant achievement and abundant grace.

Beginning as a staff nurse in stem cell transplant at Hackensack University Medical Center in 1999, Kate identified oncology and bone marrow transplant as areas of focus very early in her career while working with a 94-year-old patient during an oncology rotation and then with a 22-year-old patient. Though they were in opposite stages of life, she was inspired by each patients hope and determination and was motivated to meet their needs with cutting-edge technology and innate empathy.

As she sees it, Oncology patients give back more than you can ever give to them. It makes you want to move mountains to help them in any way you can.

A natural team builder focused on collaboration, Kate is passionate about facilitating excellent patient care and is adept at designing and implementing policies and procedures to ensure this. She is quick to credit her team. In leadership, in everything I do, its about the staff around me. Theyre with me every moment of the day to achieve what we achieve, she says.

Kate has been instrumental in operationalizing key initiatives, including helping start an onsite cellular therapy lab to provide CAR-T cell therapy to patients and pivoting during the COVID-19 pandemic to ensure the rapid creation of a high-titer convalescent plasma program while simultaneously sustaining the existing program. To this end, she is involved in updating a 12-chapter handbook for patients on bone marrow transplant.

Kate treats others as she would want to be treated, including team members and patients. Her work is centered on making sure they have the best experience possible, working with staff members every day to make sure theyre on the same page and doing the most they can do for their patients by giving them the respect they deserve and the dignity they need.

I have always had great admiration for Kates ability to lead so many people in different disciplines with such professionalism. I recently transitioned into a new role and have had the great pleasure of closely witnessing how much responsibility actually falls directly onto her plate.

Kate has the unique gift of being able to develop true relationships with her team. Her door is always open, and she is available to everyone on an individual basis and personal level. It has been one of the great honors of my nursing career to work with and learn from Kate.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

See more here:
Dedication, Achievement and Grace in Cancer Care - Curetoday.com

Posted in Stem Cell Therapy | Comments Off

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis – DocWire News

Posted: June 4, 2022 at 2:28 am

This article was originally published here

Stem Cells Transl Med. 2022 May 28:szac032. doi: 10.1093/stcltm/szac032. Online ahead of print.

ABSTRACT

MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, I 2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, I 2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.

PMID:35640138 | DOI:10.1093/stcltm/szac032

Here is the original post:
Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News

Posted in Stem Cell Therapy | Comments Off

Nerve Repair and Regeneration Market worth $11.6 billion by 2027 – Exclusive Report by MarketsandMarkets – Yahoo Finance

Posted: June 4, 2022 at 2:28 am

CHICAGO, June 2, 2022 /PRNewswire/ -- According to the new market research report "Nerve Repair and Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2027", published by MarketsandMarkets, the global Nerve Repair Market is projected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, growing at a CAGR of 12.1% from 2022 to 2027.

MarketsandMarkets_Logo

Browse in-depth TOC on "Nerve Repair Market and Nerve Regeneration Market"313 Tables 42 Figures 236 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883

The Growth in this Nerve Repair Market can be attributed to the massive geriatric population, increasing research investments on the neurological disorders, high volume of nerve injury cases, and the high prevalence of neurological diseases.

In 2021, Neurostimulation and Neuromodulation Devices accounted for the largest share of the nerve regeneration market, by product.

By product, the nerve repair & regeneration market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment is estimated to grow at the highest growth rate during the forecast period with the increasing government investments for neurologic disorders studies, and the favourable reimbursement.

By neurostimulation and neuromodulation application, internal neurostimulation and neuromodulation accounted for the largest market share in 2021.

Based on the neurostimulation and neuromodulation application, the nerve repair and regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation neuromodulation segment is expected to hold the largest share and is expected to register the highest CAGR during the forecast period. The largest share and high growth rate are driven by the increasing incidence of neurological disorders across the globe is driving the growth of this segment.

Story continues

By Biomaterials application, direct nerve repair/neurorrhaphy accounted for the largest market share in 2021.

Based on application, the nerve repair & regeneration market is segmented into direct nerve repair/neurorrhaphy, nerve grafting, and stem cell therapy. In 2021, the direct nerve repair segment accounted for the largest share of the market. This can be attributed to the increasing incidence of neurological disorders across the globe.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=883

North America was the largest regional market for nerve repair & regeneration market in 2021.

The nerve repair market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Rest of the World (Latin America, and Middle East & Africa). North America held the largest share of the nerve regeneration market in 2021, followed by Europe. The largest market share of North America is driven by the high incidence of strong presence of industry players, neurological disorders, and favourable reimbursement policies in the region.

Some of the major players operating in the global nerve repair market include Medtronic, plc. (Ireland), Boston Scientific Corporation (US), and Abbott Laboratories (US). The other players operating in the market are Axogen Corporation (US), Baxter (US), LivaNova PLC (UK), Integra LifeSciences (US), Neuronetics Inc. (US), Nevro Corp (US), NeuroPace Inc. (US), Polyganics (Netherlands), Soterix Medical Inc (US), Synapse Biomedical Inc. (US), Aleva Neurotherapeutics SA (Switzerland), Collagen Matrix Inc. (US), KeriMedical (Switzerland), BioWaveGO USA (US), NeuroSigma Inc. (US), tVNS Technologies GmbH (Germany), GiMer Medical (Taiwan), Checkpoint Surgical Inc. (US), Renishaw PLC (UK), Alafair Biosciences, Inc. (US), electroCore, Inc. (US), BlueWind Medical (Israel), Helius Medical Technologies (US), and BioControl Medical (Israel).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=883

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Neuromodulation Market by Technology- Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation), Application (Ischemia, Chronic Pain, Parkinson's, Depression, Tremor, Epilepsy, Migraine) - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/neurostimulation-devices-market-921.html

Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024https://www.marketsandmarkets.com/Market-Reports/neurodiagnostics-market-229090425.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email:sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/nerve-repair-regeneration-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/nerve-repair-regeneration.asp

Cision

View original content:https://www.prnewswire.com/news-releases/nerve-repair-and-regeneration-market-worth-11-6-billion-by-2027--exclusive-report-by-marketsandmarkets-301560225.html

SOURCE MarketsandMarkets

See the original post here:
Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance

Posted in Stem Cell Therapy | Comments Off

CPX-351 in Treatment of AML and Clinical Considerations – OncLive

Posted: June 4, 2022 at 2:28 am

Richard Stone, MD: How do we treat the patient like this?

Eunice Wang, MD: In this instance, Id look at the overall presentation of the patient. AML [acute myeloid leukemia] therapy in the current era requires that we individualize the treatment regimen for the patient and disease. This woman has undergone intensive or definitive therapy for her breast cancer. Shes still functionally active, has an excellent performance status, and doesnt have any evidence of organ dysfunction, eg, liver, kidney, or heart. Her activity level is normal. Shes continuing to work full-time, chasing high school students around.

Id think about offering her an intensive chemotherapy approach, potentially followed by allogeneic stem cell transplant for curative intent. Because we know that in most patients with a secondary therapyrelated AML, the best outcomes are achieved by the performance of an allogeneic stem cell transplant as postconsolidation therapy. What are your thoughts on this?

Richard Stone, MD: I agree with everything you said. When I think about intensive chemotherapy, I think about whether the patient can tolerate it and whether it will benefit the patient. Because there are certain patients who can tolerate intensive chemotherapy, but Im not sure [they] would benefit from it. Its still an open question. In other words, patients with a TP53 mutation and complex karyotype may not benefit from intensive chemotherapy. They may not [have] better [results] with azacitidine and venetoclax, but at least theyre not going to be as sick.

Without any proof, I have a predilection to treat the patients [with high-risk disease] with less intensive chemotherapy, because it isnt likely to be worse and will likely be better tolerated. Thats unproven at the moment. For this patient, Id use an intensive approach because of her age, favorable mutational status, and good performance status. I have a similar view that she should get an intensive regimen. What do you think are the choices for an intensive regimen?

Eunice Wang, MD: This patient is over the age of 60, which makes it more straightforward. But based on her age and the diagnosis of a secondary therapyrelated AML, my preference would be to treat her with CPX-351, or liposomal cytarabine-daunorubicin. That offers her the best opportunity to be free of disease in 3 to 5 years.

There were the results of a phase 3 randomized clinical trial where patients aged 60 to 75 [years] with secondary AML were [randomly assigned] to receive up-front induction of chemotherapy with either CPX-351that liposomal formulation is dosed on days 1, 3, and 5[or] the standard continuous infusion [of] cytarabine and daunorubicin, our 7+3 gold standard. In that trial, patients could get 2 cycles of the CPX-351 induction or 7+3. They could get consolidation with a CPX-351 vs a 5+2. Eligible patients could then go on to subsequent transplant.

The 5-year results were published in 2021 and substantiate the early findings that led to FDA approval, where about 18% in the CPX-351 group and 8% in the 7+3 group were alive and disease-free at 5 years. Of the patients who had gotten CPX-351 followed by transplant, most impressively, 53% were alive. The overall survival for those patients who had gone to subsequent transplant from CPX-351 hadnt been reached yet. I was impressed with that because in the past, patients who got therapy-related AML rarely went into remission or long-term response. Very few of themless than 10% with standard therapy[survived for] 3 to 5 years. Based on those data, Id be offering CPX-351 to this patient.

The only question would beand I throw this back to youwhat if she were 59 [years old]? Would you treat her similarly? Because the trial was for patients aged 60 to 75 years. If she were 55 or 45 [years old], would you do the same thing? Or would you restrict your interpretation of that trial to the [patients aged] 60 to 75?

Richard Stone, MD: Thats a great question. The FDA believes you could extend the [use] of CPX-351 to younger folks because they approved it in an age-agnostic fashion, which was surprising because, as you pointed out, the data were only [from results of] patients aged 60 to 75 [years]. Its possible that a 7+3 regimen would have been better than CPX-351 for younger patients. They did a trial in all ages, [but] it didnt show better results. They did a trial with older adults, and it was only the ones who had secondary AML who seemed to benefit from CPX-351 compared with 7+3. Its a little unclear, but I believe its because CPX-351 seems to release ARA-C [cytosine arabinoside] and daunorubicin, a so-called favorable molar ratio, to kill the cells. Thats more theoretical, but its true. It also [remains] in the bone marrow a little longer, which accounts for its mild suppression. Maybe thats another reason why its a little better.

The answer to your question is that Id use it in a younger patient who had secondary AML. Curiously, in another post hoc analysis done by R. Coleman Lindsley, [MD, PhD], of the CPX-351 vs 7+3 trial that you mentioned, [patients] with TP53 mutations didnt benefit from CPX-351 compared with 7+3. Thats another situation where you throw up your hands. [These] were [patients aged] 60 to 75, but Id use it in the right patient under 60 [years of age]. In fact, theres an ongoing trial in Europe for patients regardless of their history of MDS [myelodysplastic syndrome] or prior treatment that will compare 7+3 with CPX-351. Maybe it will turn out to be a better induction regimen than 7+3 alone. We need to wait and see.

We talked about CPX-351 compared with azacitidine-venetoclax in the retrospective studies that were published at the American Society of Hematology meeting. CPX-351 is similar to 7+3 chemotherapy, but different in that its given episodically on days 1, 3, and 5. As you mentioned, its possible to give this [treatment] outpatient if the patient isnt ill, and we do that too. It saves hospitalization. Its also financially toxic to the inpatient service to pay for CPX-351, which is very expensive compared with 7+3. But you may save money by not admitting the patient for as many days. We bring them in on day 10 at the start of their expected nadir, because almost all of them will [have] some fever and neutropenia, and its easier to have them in the hospital when that happens than outpatient [service].

We find CPX-351 to be well tolerated in general, with no hair loss, minimal GI [gastrointestinal] toxicity, and as you mentioned, prolonged myelosuppression. Those are the main considerations with CPX-351. Its cardiotoxic. Its hard to know how it compares with standard daunorubicin, or even doxorubicin, for those who have secondary AML. [For] your patient, its important to consider the prior doxorubicin if they were treated for breast cancer or another cancer. We get echocardiograms frequently for our CPX-351 patients. Any other thoughts about that, Eunice?

Eunice Wang, MD: As you mentioned, there are a lot of things to recommend in terms of the toxicity profile. Our patients are excited about the fact that they dont lose their hair and [wont] be inpatient for 40, 50, or 60 days. In general, there are still the complications from infection, but the ability to do part of the regimen outpatient and then do all the regimen outpatient in the consolidation setting while waiting for possible transplant improves quality of life. [It] has been demonstrated in other studies that, as compared with 7+3 and standard consolidation, patients have almost 50% improved quality-of-life scores on various questionnaires when asked about the comparison between the 2. Thats an important thing to keep in mind as were tailoring therapy for the patient and the disease.

Transcript edited for clarity.

Continued here:
CPX-351 in Treatment of AML and Clinical Considerations - OncLive

Posted in Stem Cell Therapy | Comments Off

High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study – AJMC.com Managed Markets Network

Posted: June 4, 2022 at 2:28 am

As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.

A new French study is highlighting the high cost burden associated with multiple myeloma (MM), as well as variability in treatments used in later lines of therapy. The findings were published in The European Journal of Health Economics.

As more treatments continue to enter the market for MM, the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.

Understanding patient [health care resource utilization] patterns, disease burden, and health-related expenditure is important when evaluating the potential value of new treatments and facilitates targeted improvements in MM management, explained the researchers. Analyses of health insurance databases can guide public health care decisions, monitor various types of medical expenditures, inform epidemiological studies, evaluate medical practices or health system experimentations, and can be used for international comparisons.

The researchers included real-world data from 6400 patients diagnosed with MM between 2013 and 2018, finding an average annual cost of 58,300 (approximately $62,500). Notably, costs were highest in the first year after diagnosis, with a mean total annual cost per patient in the first exceeding 72,400 (approximately $77,600) and the monthly exceeding 7100 (approximately $7600).

The cost of treatment and hospitalizations contributed the most to costs, with an overall rate of 6.3 hospitalizations per patient per year. Nearly all (96.6%) patients underwent some type of hospitalization for any cause, and had at least 1 overnight hospital stay (93.1%). Notably, hospitalization accounted for a greater proportion (48.6%) of total costs in the first year after diagnosis than the average of the rest of the years of follow-up (38.1%).

With each line of therapy (LOT), the monthly costs associated with treatment increased. Monthly costs increased from 2447 (approximately $2600) during the first LOT to 7026 (approximately $7500) during fifth LOT and subsequently.

Increase in hospitalisation costs associated with subsequent LOT was likely related to the increasing age and decreasing health of patients requiring ongoing treatment for MM, described the researchers. This is supported by a retrospective study of hospitalised French patients, which identified an association between age and duration of hospital stay. The cost of hospitalisations for an event of interest constituted a greater proportion of hospitalisation costs among patients at later LOT, indicating that declining patient condition conferred a greater burden to the health care system beyond the cost of drugs.

Health care resource utilization was lower for patients who received stem cell transplantation, although their hospital stays were associated with higher costs, largely due to the more expensive procedure.

Nearly all (97.1%) patients received an identifiable treatment throughout the study period, with the most frequent regimens being those that included bortezomib. Bortezomib-based regimens accounted for 62.2% of the 8865 regimens, and 96.7% of patients received the combination as their first LOT. During second and third LOT, lenalidomide-based regimens were most common. By the fourth line of therapy and later, the researchers identified 37 different regimens.

Reference

Bessou A, Colin X, Nascimento J, et al. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France usingthe Systme National des Donnes de Sant (SNDS) database:a retrospective cohort study. Eur J Health Econ. Published online May 25, 2022. doi:10.1007/s10198-022-01463-9

Excerpt from:
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network

Posted in Stem Cell Therapy | Comments Off

3D Cell Culture Market Size, Trends, Share, Research Report Study, Regional and Industry Analysis, Forecast to 2030 The Greater Binghamton Business…

Posted: June 4, 2022 at 2:27 am

United StatesReport Oceanpublished a new report on the3D Cell Culture Market The study includes an in-depth analysis of regional trends and market growth in North America, Europe, Asia-Pacific, and Middle East Africa. This study report also examines the challenges that are negatively impacting the industrys growth and outlines a strategy adopted by companies during 2022 to 2030.

Global 3D Cell Culture Market is estimated to reach $4,899 billion by 2024; growing at a CAGR of 23.3% from 2016 to 2024.

3D cell culture is the culture of biological cells in micro-assembles devices, where artificially created three-dimensional environment supports the growth of these cells. The micro-environment parameters of these growing cells can be controlled and monitored to a certain extent. Driven by advancements in the field of cell imaging and analytical systems, cells have been increasingly grown in 3D cell culture and have proved to be useful in many applications. Moreover, they are widely used in tissue engineering and drug discovery, owing to its ability to provide physiologically relevant and accurate data for various in-vivo test. 3D cell culture is widely used in various application such as, disease pathology, tissue morphogenesis and engineering, gene and protein expression, regenerative medicine, and others.

Request To Download Sample of This Strategic Reporthttps://reportocean.com/industry-verticals/sample-request?report_id=RO136

Increase in investment by pharmaceutical and biotechnology companies on 3Dcell culture, and growth in number of patients in need for organ transplantation are the key factors supporting the growth of the global 3D cell culture market. Moreover, ban on animal research and testing is also expected to drive 3D cell culture across various applications. However, high initial investments may restrain the growth of the market. Furthermore, development of 3D cell culture for formulating personalized cosmetics would provide growth opportunities for the market in the near future.

The global 3D cell culture market is categorized into technology, application, and end-user. By technology, the market is segmented into extracellular matrices, bioreactors, gels, Scaffold free platform, and microchips. By application, the market is sub-segmented into research, drug discovery, tissue engineering, clinical applications, and stem cell biology. Furthermore, end-user is segmented into research laboratories & institutes, biotechnology & biopharmaceutical industry, and hospital & diagnostic centers.

By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers UK, Germany, France Italy, and others. Asia-Pacific covers China, Japan, India, South Korea, and others. RoW covers South America, Middle East, and Africa.

Key market players comprise Merck & Co., Inc., 3D Biotek LLC, Lonza Group, Kuraray Co., Ltd., Corning Incorporated, Becton, Dickinson and Company, Advanced Biomatrix, Inc., Thermo Fisher Scientific Inc., VWR International, LLC, and Global Cell Solutions, Inc., among others.

Request To Download Sample of This Strategic Reporthttps://reportocean.com/industry-verticals/sample-request?report_id=RO136

The key takeaways from the reportThe report will provide a detailed analysis of Global 3D Cell Culture Market with respect to major segments such as technology, application, end-user, and geographyThe report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024Comprehensive analysis of market dynamics including factors and opportunities will be provided in the reportAn exhaustive regional analysis of Global 3D Cell Culture Market from 2015 to 2024 has been included in the reportProfile of the key players in the Global 3D Cell Culture Market will be provided, which include key financials, product & services, new developments, and business strategiesScope of the Global 3D Cell Culture MarketTechnology Segments

Extracellular MatricesBioreactorsGelsScaffold Free PlatformMicrochipsApplication Segments

ResearchDrug DiscoveryTissue EngineeringClinical ApplicationsStem Cell BiologyEnd-User Segments

Research Laboratories & InstitutesBiotechnology & Biopharmaceutical IndustryHospital & Diagnostic Centers

For More Information or Query or Customization Before Buying, Visithttps://reportocean.com/industry-verticals/sample-request?report_id=RO136Geography Segments

North AmericaU.S.CanadaMexicoEuropeUKGermanyFranceItalyOthersAsia-PacificIndiaChinaJapanSouth KoreaOthersRoWSouth AmericaMiddle EastAfrica

Table of content:

Request for Full Report

https://reportocean.com/industry-verticals/sample-request?report_id=RO136

Key Questions Answered in the Market Report

? How did the COVID-19 pandemic impact the adoption of by various pharmaceutical and life sciences companies?? What is the outlook for the impact market during the forecast period 2021-2030?? What are the key trends influencing the impact market? How will they influence the market in short-, mid-, and long-term duration?? What is the end user perception toward?? How is the patent landscape for pharmaceutical quality? Which country/cluster witnessed the highest patent filing from January 2014-June 2021?? What are the key factors impacting the impact market? What will be their impact in short-, mid-, and long-term duration?? What are the key opportunities areas in the impact market? What is their potential in short-, mid-, and long-term duration?? What are the key strategies adopted by companies in the impact market?? What are the key application areas of the impact market? Which application is expected to hold the highest growth potential during the forecast period 2021-2030?? What is the preferred deployment model for the impact? What is the growth potential of various deployment models present in the market?? Who are the key end users of pharmaceutical quality? What is their respective share in the impact market?? Which regional market is expected to hold the highest growth potential in the impact market during the forecast period 2021-2030?? Which are the key players in the impact market?

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Excerpt from:
3D Cell Culture Market Size, Trends, Share, Research Report Study, Regional and Industry Analysis, Forecast to 2030 The Greater Binghamton Business...

Posted in Illinois Stem Cells | Comments Off

Page 407«..10 20..406407408 409..420 430..»

First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics – Tech Times

How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into ‘Safer’ Covid-19 Vaccines: Study – ABP Live

Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? – Kaiser Health News

Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater…

Dedication, Achievement and Grace in Cancer Care – Curetoday.com

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis – DocWire News

Nerve Repair and Regeneration Market worth $11.6 billion by 2027 – Exclusive Report by MarketsandMarkets – Yahoo Finance

CPX-351 in Treatment of AML and Clinical Considerations – OncLive

High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study – AJMC.com Managed Markets Network

3D Cell Culture Market Size, Trends, Share, Research Report Study, Regional and Industry Analysis, Forecast to 2030 The Greater Binghamton Business…

Categories

Archives

Recommended Sites

Contact Us

Recent Posts